📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-18 14:55
169 analysed today
FollowTelegram
169
Today
150,120
All-time analysed
43,024
Positive
6,671
Negative
91,702
Neutral
8,655
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Eiko LifeSciences Allots 3.05 Lakh Shares on Warrant Conversion; Collects ₹1.26 Cr
Eiko LifeSciences Limited approved the allotment of 3,05,000 equity shares of face value ₹10 at an issue price of ₹55 per share (including ₹45 premium) upon warrant conversion. The company received ₹1,25,81,250 representing the final 75% balance (₹41.25 per warrant). Promoter Bhavesh Dhirajlal Tanna converted 1,30,000 warrants (raising his stake from 5.86% to 6.62%), while non-promoter V Square Pharmachem converted 1,75,000 warrants (taking a 1.19% stake). Post-allotment, paid-up share capital increases to ₹14.65 crore (1,46,50,854 shares), with 26,45,000 total warrants still outstanding for conversion.
Confidence: HIGH
What changedConversion of 3,05,000 preferential warrants into equity shares, raising ₹1.26 crore.
Why it mattersAdds ₹1.26 crore to the company's equity capital base at ₹55 per share (above the current market price of ₹48.1), leading to mild dilution of ~2.1% on the previous share count.
Shares allotted: 3,05,000Issue price per share: Rs. 55Amount received (75%): Rs. 1,25,81,250Post-issue paid-up capital: Rs. 14,65,08,540Total warrants pending conversion: 26,45,000
📅 Short termMarginal supply expansion once the newly allotted 3.05 lakh shares receive listing and trading approval from the exchange.
📈 Long termLimited operational impact; full conversion of the remaining 26.45 lakh warrants would dilute existing equity base by ~18%.
⚠ Risk flags
- Potential future dilution upon conversion of 26.45 lakh outstanding warrants
Key Highlights
Allotted 3,05,000 equity shares of ₹10 face value at an issue price of ₹55 each
Received balance 75% consideration aggregating to ₹1,25,81,250 (₹41.25 per warrant)
Promoter Bhavesh Dhirajlal Tanna stake rises from 5.86% to 6.62% (allotted 1,30,000 shares)
Non-promoter V Square Pharmachem allotted 1,75,000 shares (1.19% post-issue holding)
26,45,000 total warrants remain pending conversion across holders
👀 What to Watch
Monitor subsequent conversion notices and timing for the remaining 26.45 lakh warrants to assess cumulative equity dilution and cash inflows.
Rs 16.75 Cr Revenue: Eiko Lifesciences Reports 56% YoY Revenue Growth in Q1 FY27
Eiko Lifesciences reported a strong year-on-year performance for Q1 FY27, with consolidated revenue rising 56.4% to Rs 16.75 Cr compared to Rs 10.71 Cr in Q1 FY26. Consolidated Net Profit grew 35% YoY to Rs 1.51 Cr, supported by the scaling of its core Specialty Chemicals business and a new contribution from the Logistics segment. However, on a sequential basis, revenue declined 8.7% from Rs 18.34 Cr in Q4 FY26, while PAT remained relatively flat. The new Logistics segment contributed Rs 1.50 Cr to the top line with a healthy segment margin of 19.2%.
Confidence: HIGH
What changedThe company has transitioned to a multi-segment reporting structure with the formal commencement and contribution of its Logistics Services business.
Why it mattersFor a micro-cap company with an Rs 81 Cr market cap, the 56% YoY revenue growth and successful diversification into logistics are significant for scaling the business, though sequential momentum slowed.
Consolidated Revenue (Q1 FY27): Rs 16.75 CrYoY Revenue Growth: 56.4%Consolidated PAT (Q1 FY27): Rs 1.51 CrLogistics Revenue Contribution: 8.9%Q1 Revenue vs TTM Revenue: 31.6%
📅 Short termThe stock may see positive sentiment due to strong YoY growth and diversification, though the sequential revenue dip might temper the rally.
📈 Long termThe addition of the Logistics segment provides a higher-margin revenue stream, but the company's small scale makes it sensitive to raw material price volatility in the chemical segment.
⚠ Risk flags
- Sequential revenue decline of 8.7% compared to Q4 FY26
- High raw material dependency (Cost of materials was 83% of standalone revenue)
- Small market capitalization leads to high volatility
Key Highlights
Consolidated Revenue from operations increased 56.4% YoY to Rs 16.75 Cr.
Consolidated Net Profit rose to Rs 1.51 Cr, up from Rs 1.12 Cr in the year-ago period.
The new Logistics Services segment contributed Rs 1.50 Cr to revenue and Rs 0.29 Cr to segment profits.
Specialty & Fine Chemicals segment revenue grew 81.5% YoY to Rs 15.25 Cr.
Basic EPS for the quarter improved to Rs 0.91 from Rs 0.66 in Q1 FY26.
👀 What to Watch
Investors should monitor the sustainability of the new Logistics segment's margins and watch for a recovery in sequential revenue growth in the core Specialty Chemicals business.
